First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as
first-line treatment in patients with metastatic triple-negative breast cancer.